Patent application number | Description | Published |
20110038866 | IMPROVED FIBRONECTIN-BASED BINDING MOLECULES AND USES THEREOF - The invention provides fibronectin type III (Fn3)-based binding molecules that bind to a specific target antigen. The invention further provides bispecific Fn3-based binding molecules that bind to two or more targets simultaneously. The Fn3-based binding molecules of the invention can also be linked together to form multispecific Fn3-based binding molecules, and/or can be conjugated to a non-Fn3 moiety, such as, Human Serum Albumin (HSA), for improved half life and stability. The invention also provides methods for generating, screening and using Fn3-based binding molecules in a variety of therapeutic and diagnostic applications. | 02-17-2011 |
20120129766 | METHODS OF TREATING FGF21-ASSOCIATED DISORDERS - The invention relates to the identification of new polypeptide and protein variants of fibroblast growth factor 21 (FGF21) that have improved pharmaceutical properties. Also disclosed are methods for treating FGF21-associated disorders, including metabolic conditions. | 05-24-2012 |
20120208704 | UNIVERSAL FIBRONECTIN TYPE III BOTTOM-SIDE BINDING DOMAIN LIBRARIES - The invention pertains to a natural-variant combinatorial library of fibronectin Type 3 domain (Fn3) polypeptides useful in screening for the presence of one or more polypeptides having a selected binding or enzymatic activity. The library polypeptides include (a) regions A, AB, B, C, CD, D, E, EF, F, and G having wildtype amino acid sequences of a selected native fibronectin Type 3 polypeptide or polypeptides, and (b) loop regions AB, CD, and EF having selected lengths (Bottom Loops). The Fn3 may also have loop regions BC, DE, and FG having wildtype amino acid sequences, having selected lengths, or mutagenized amino acid sequences (Top Loops). | 08-16-2012 |
20130064823 | COMPOSITIONS AND METHODS OF USE FOR THERAPEUTIC LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) MULTIVALENT ANTIBODIES - The present disclosure relates to an antibody or antigen binding fragment having at least two receptor binding do mains for two different binding sites of LRP6 and compositions and methods of use thereof. | 03-14-2013 |
20130129724 | DUAL FUNCTION PROTEINS FOR TREATING METABOLIC DISORDERS - The present invention relates to the identification of new proteins comprising fibroblast growth factor 21 (FGF21) and other metabolic regulators, including variants thereof, known to improve metabolic profiles in subjects to whom they are administered. Also disclosed are methods for treating FGF21-associated disorders, GLP-1-associated disorders, and Exendin-4-associated disorders, including metabolic conditions. | 05-23-2013 |
20140050725 | LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) - HALF LIFE EXTENDER CONSTRUCTS - The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit. | 02-20-2014 |
20140057807 | FIBRONECTIN CRADLE MOLECULES AND LIBRARIES THEREOF - The here described invention discloses a combination of a top and bottom loop binder library using the CD and the FG loops of a number of FnIII domains (FnIII) (e.g., FnIII | 02-27-2014 |
20140161796 | SINGLE CHAIN PROTEINS WITH C-TERMINAL MODIFICATIONS - The invention pertains to an isolated V | 06-12-2014 |
20150030617 | LOW DENSITY LIPOPROTEIN - RELATED PROTEIN 6 (LRP6) - HALF LIFE EXTENDER CONSTRUCTS - The present invention relates to LRP6 constructs that bind to LRP6 receptor. The LRP6 constructs comprise at least one LRP6 binding moiety and a half-life extender molecule such that the LRP6 construct inhibit the Wnt signaling pathway without potentiation of the Wnt signal. The LRP6 constructs also have an increased half-life to provide more time for the therapeutic benefit. | 01-29-2015 |